KALA BIO, Inc. Common Stock (KALA) is a publicly traded Healthcare sector company. As of November 9, 2026, KALA trades at $0.16 with a market cap of $3.02M and a P/E ratio of -0.11. KALA moved +0.00% today. Year to date, KALA is -99.50%; over the trailing twelve months it is -99.57%. Its 52-week range spans $0.11 to $1,030.00. Rallies surfaces KALA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Kala Bio signs LOI to buy nationwide telehealth platform for about $15 million: Kala Bio signed a non-binding letter of intent to acquire a privately held company supporting a 50-state telehealth platform for about $15 million in cash and stock. The target reported $12.7 million in trailing-12-month revenue through August 2026 and was described by management as cash-flow positive.
| Metric | Value |
|---|---|
| Price | $0.16 |
| Market Cap | $3.02M |
| P/E Ratio | -0.11 |
| EPS | $-3.31 |
| Dividend Yield | 0.00% |
| 52-Week High | $1,030.00 |
| 52-Week Low | $0.11 |
| Volume | 5.65K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-26.98M |
| Gross Margin | 0.00% |
KALA analyst coverage data. Average price target: $0.00.